Best Life Sciences Companies in Alberta, Canada

Developer of minimally invasive spinal surgery devices. The company develops surgical techniques, implants, and instruments that conserve spinal bone, nerve, and muscle tissues during orthopedic surgeries. The company offers deployable grafting, pedicular fixation, interbody fusion, retractor, liquid tissue matrix, amniotic wound covering, spinal fixation, allograft, and facet fixation systems. The OptiMesh Deployable Grafting System works by allowing implants to be inserted empty and then deployed to their full size, once in position.

Funding rounds

• Nov 2025Unattributed$8.8M
• Jul 2024Unattributed$25M
• May 2023Unattributed$5M
• Sep 2021Venture Debt$15M

Founders & team

Brian SniderChief Executive Officer

Investors

Affinity Capital Management, Oak Ridge Financial, Hermed Capital, Horizon, SV Health Investors, 1315 Capital

Tech stack

Animate.CssAstraBeaver BuilderCloudflareCloudflare Bot ManagementCore-Js

Developer of a blood test device to detect breast cancer. The company offers the Syantra DX device for blood-based cancer detection test that utilizes a combination of biomarkers and artificial intelligence-generated algorithms for molecular diagnostics. It captures and decodes changes in how the body is functioning. It enables earlier detection and effective treatment of cancer.

Funding rounds

• Mar 2026Grant (prize money)$2.4M
• Sep 2024Series A$3.6M
• Jan 2022Series A$6.8M
• Jun 2021Seed—

Founders & team

Kenneth FuhCo-FounderBob ShepherdCo-Founder & COOKristina RinkerChief Scientific Officer and Founder

Investors

The51, Canaccord Genuity Group, Plug and Play Tech Center, Accelerate Fund, Department of War, Innovate Calgary

Tech stack

CloudflareGoogle AnalyticsHstsHttp/3JqueryMicrosoft 365

Oncolytics Biotech is a development-stage biotechnology company that develops oncolytic viruses for use as cancer therapeutics. The company's leading product, REOLYSIN, is developed from the reovirus. Oncolytics Biotech claims that the virus has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. The wholly owned subsidiaries of the Company include Oncolytics Biotech (Barbados) and Oncoltics Biotech (US).

Funding rounds

• Apr 2025Post IPO$20M
• Oct 2010Post IPO$24M
• Post IPO$4.1M

Founders & team

Matt CoffeyPresident and Chief Executive Officer

Investors

Paradigmcap, RBC Capital Markets, Alumni Capital

Tech stack

AstraCloudflareCloudflare Bot ManagementCookieyesCore-JsElementor

Zenith Epigenetics is a developer of small molecule BET inhibitors for cancer and autoimmune disorders. The company’s proprietary epigenetic drug discovery platform functions by inhibiting BET bromodomains. Its lead product, ZEN-3694, is a BET inhibitor developed for hematological malignancies and solid tumors including prostate cancer. It can be act as a single therapeutic solution for prostate cancer.

Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins. The company has developed a platform called EntoEngine that assists in the production of serum-free medical products. They also offer various products and services related to recombinant proteins.

Funding rounds

• Jun 2025Series A$8M
• Feb 2023Seed$11.2M
• Feb 2021Seed$2.2M
• Aug 2020Seed$150K

Founders & team

Matt Anderson-BaronChief Executive Officer

Investors

Y Combinator, Bee Partners, Toyota Ventures, Builders VC, AgFunder, Amplify Capital

Developer of therapeutics for cancer treatment. It offers technology that targets solid tumours that improve patient outcomes and fight against cancer which include colorectal cancer, breast cancer and lung cancer.

Funding rounds

• Jan 2026Post IPO$880K
• Jul 2025Post IPO$291.5K
• Jan 2025Post IPO$696.8K

Founders & team

Thomas O ShaughnessyCEO

Tech stack

Framer SitesGodaddyGoogle Font ApiHstsHttp/3Microsoft 365

Developer of mRNA-based therapeutics for cancer and covid-19 treatment. The company's mRNA vaccines are customized based on the patient's tumor-specific mutations to induce an immune response. It generates strong T-cell responses that aim to kill cancer cells and destroy tumors. Also, developed PTX-COVID19-B and PTX-COVID19-LT for covid-19 treatment.

Funding rounds

• May 2025Conventional Debt$711.6K
• May 2025Series A$711.6K
• Mar 2025Series A$209.8K
• Jan 2025Series A$395.4K

Founders & team

Eric MarcussonCo-FounderBrad SorensonFounder & President & CEO

Investors

NGen, Gates, JLABS

Tech stack

Animate.CssApache Http ServerBootstrapBunnyGodaddyGoogle Analytics

Manufactures of benchtop NMR spectrometers. The company develops and manufactures compact, portable, benchtop Magnetic Resonance Imaging and Spectroscopy products. The NMR instruments are used for teaching, biotech and pharma, polymer research, food science, synthetic chemistry, reaction monitoring/process analytical technology, mining and minerals, oil and gas, security and defense, cannabis, and more.

Wearable devices for neuropathy patients and athletes. It develops a sensor-based product, Orpyx SI, the sensory insoles with remote patient monitoring allows users to manage and prevent diabetic foot ulcers and limb loss through advanced foot sensor technology and real-time analytics. The insoles can fit above the shoe and capture pressure data from the user's feet. The pressure data is then wirelessly transmitted from the shoe inserts to a smartwatch. The smartwatch alerts the user at extreme pressure levels to modify their behaviour and avoid damage. The device can be used to track neuropathy and is FDA cleared. Other product lines include SurroSense Rx system, Orpyx LogR solution and SurroGai Rx system.

Funding rounds

• Sep 2024Series B$20M
• Oct 2023Series A$11K
• Jul 2020Series A$5.6M

Founders & team

Breanne EverettCo-Founder & CEO

Investors

Aphelion Capital, Thin Air Labs, Intergenconnect, Relentless Venture Fund, Viewpoint Group, ICM Asset Management

Tech stack

Apple Icloud MailBluehostCloudflareCloudflare Bot ManagementCookie ScriptCore-Js

Developer of medical device to treat brain aneurysms. The company has developed a hybrid polymer-metal flow-diverting stent to cure brain aneurysms. Also, its proprietary stent delivery system is used to navigate to bypass the aneurysm under angiographic guidance.

Funding rounds

• Dec 2024Series A$27M
• Aug 2021Seed$4.7M
• Feb 2020Seed$846.7K

Founders & team

John WongCo-Founder & CEOAlim MithaCo-Founder

Investors

Metis Innovative, ShangBay Capital, University of Calgary, Thin Air Labs, Wharton Alumni Angels, Bluesky Equities

XORTX is a therapeutics company spun out from the University of Florida, with a focus on orphan disease markets such as rare kidney diseases caused by improper uric acid metabolism. Its drug pipeline includes therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Phase 1), and Diabetic Nephropathy (DN), which target the renin-angiotensin-aldosterone system (RAAS).

Funding rounds

• Aug 2025Post IPO$83.3K
• Jun 2025Post IPO$925K
• Feb 2024Post IPO$1.8M
• Jan 2021Post IPO$6.1M

Founders & team

Allen DavidoffPresident and CEO

Tech stack

Apache Http ServerBootstrapFancyboxGoogle AnalyticsHcaptchaHsts

Developer of medical device for organ preservation technology. It offers a perfusion machine designed to preserve and transport kidneys for transplantation to improve patient outcomes and reducing wait times.

Funding rounds

• Apr 2025Seed$1.9M
• Feb 2025Seed—

Founders & team

Daniel SalamonCo-Founder & COO

Investors

Kidney, Leva Capital, Threshold Impact, Startup TNT, Accelerate Fund